Paper Details

  1. Home
  2. Paper Details

Sustained complete response after maintenance therapy with topotecan and erlotinib for recurrent cervical cancer with distant metastases.

Author: Callegaro-FilhoDonato, KavanaghJohn J, NickAlpa M, RamirezPedro T, SchmelerKathleen M

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.

Overview

A 53-year-old woman with recurrent metastatic cervical cancer who had previously been treated with radiotherapy, cisplatin, and topotecan had a sustained response to maintenance therapy with topotecan and erlotinib. The patient is currently without evidence of disease 5 years after completing the topotecan-erlotinib treatment.
Paper Details　
Original Abstract of the Article :
INTRODUCTION: Recurrent cervical cancer is associated with a poor prognosis. Most treatment responses are partial and of short duration. The development of new therapies is vital to improve treatment for recurrent disease. Epidermal growth factor receptor (EGFR) inhibitors may have a role in this se...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3934679/

データ提供：米国国立医学図書館（NLM）

A Ray of Hope in the Desert of Recurrent Cervical Cancer

The desert of cancer research is vast and unforgiving, with recurrent cervical cancer presenting a particularly challenging landscape. This study highlights a case of a patient with recurrent cervical cancer who achieved a sustained complete response after receiving a unique combination of therapies, including topotecan and erlotinib.

A Journey Through Challenging Terrain

The patient's journey was marked by multiple recurrences, navigating a challenging path with various treatment approaches. The researchers meticulously documented the patient's experience, highlighting the importance of personalized therapies and the potential benefits of combining different treatment modalities. It's like charting a course through a treacherous desert, finding the right strategies to overcome obstacles.

The Power of Combination Therapy

The study suggests that combining topotecan and erlotinib may be a promising approach for treating recurrent cervical cancer, offering hope for patients facing this daunting challenge. It's like finding a hidden oasis in the desert of treatment options, a place where a combination of resources can offer a path to recovery.

Dr. Camel's Conclusion

This case study highlights the importance of exploring new treatment strategies and combining different approaches to address the complexities of cancer. It's a reminder that even in the most challenging landscapes, we can find pathways to hope and recovery, like discovering a hidden oasis in the vast desert of cancer research.

Date :
  1. Date Completed 2014-02-27
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

24575024

DOI: Digital Object Identifier

PMC3934679

Related Literature

Article Analysis
・Side Effects of topotecan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.